Get informed when a big investor buys or sells
+ FollowLoading insider trades…
Loading congress trades…
| Market cap | $1.00 |
|---|---|
| Enterprise Value | $2.09 Million |
| Earnings per Share | $-0.23 |
| Beta | 2.8 |
| Outstanding Shares | 5,412 |
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.71 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 1 |
| Debt to Equity | -0.28 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Operating as a biopharmaceutical firm, NovAccess Global Inc. focuses on developing innovative immunotherapies to treat individuals with brain tumors across the United States. Their primary expertise is in pioneering research that leverag...